Skip to main content

Lucid Diagnostics Inc.

corporate_fare Company Profile

Lucid Diagnostics Inc.

LUCD·NASDAQ·Industrial Applications And Services·CIK 0001799011

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on cancer prevention. The company targets millions of patients with gastroesophageal reflux disease (GERD), or chronic heartburn, who are at risk of developing esophageal precancer and esophageal adenocarcinoma (EAC). Lucid's primary product is the EsoGuard Esophageal DNA Test, which uses samples collected with the EsoCheck Esophageal Cell Collection Device. Lucid believes this combination is the first and only commercially available diagnostic test designed to prevent EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The EsoGuard test is a bisulfite-converted targeted next-generation sequencing (NGS) DNA assay. It quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1), using surface esophageal cells. Analytical validation tests showed EsoGuard has approximately 97% analytical sensitivity, 95% analytical specificity, 98% analytical accuracy, and 100% inter-assay and intra-assay precision. In screening studies, EsoGuard demonstrated a positive predictive value (PPV) of 30-33% and a negative predictive value (NPV) of 99% for detecting Barrett's esophagus (BE) and EAC. The EsoCheck device, which is FDA 510(k)-cleared and CE Mark certified, is a noninvasive swallowable balloon capsule catheter. It is designed for in-office targeted sampling of surface esophageal cells in a procedure lasting less than two minutes. The device consists of a vitamin-sized semi-rigid plastic capsule tethered to a thin silicone catheter, from which a soft inflatable silicone balloon with textured ridges emerges to swab cells.

Lucid Diagnostics Inc. (NASDAQ:LUCD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for LUCD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Lucid Diagnostics Reports Going Concern Warning Amidst Heavy Dilution and Mounting Losses

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.71M
Net Income
-$58.01M
Op. Cash Flow
-$46.48M
Free Cash Flow
-$46.68M
Gross Profit
-$1.96M
Operating Income
-$49.64M
Cash & Equivalents
$34.7M
Debt / Equity
0.00×
Net Margin
-12.33×
Shares Outstanding
131.1M sh
Source: 10-K · filed 2026-03-25 · accession 0001437749-26-009805
$0.375 +0.62% today
52-week range · as of 2026-11-12 $0.303 – $1.63
Market cap
$77.14M
Volume
2.3M (0.2× avg)
3-mo avg 9.4M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LUCD - Filings & News (Page 2)

LUCD
Mar 25, 2026, 4:56 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $0.375 info
Change: -$0.835 (-69%) info
Market Cap: $77.141M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets